Chimeric antigen receptors (CARs) link an antigen recognition domain to intracellular signaling domains to redirect T cell specificity and function. T cells expressing CARs with CD28/CD3 or 4-1BB/CD3 signaling domains are effective at treating refractory B cell malignancies but exhibit differences in effector function, clinical efficacy, and toxicity that are assumed to result from the activation of divergent signaling cascades. We analyzed stimulationinduced phosphorylation events in primary human CD8 + CD28/CD3 and 4-1BB/CD3 CAR T cells by mass spectrometry and found that both CAR constructs activated similar signaling intermediates. Stimulation of CD28/ CD3 CARs activated faster and larger-magnitude changes in protein phosphorylation, which correlated with an effector T cell-like phenotype and function. In contrast, 4-1BB/CD3 CAR T cells preferentially expressed T cell memory-associated genes and exhibited sustained antitumor activity against established tumors in vivo. Mutagenesis of the CAR CD28 signaling domain demonstrated that the increased CD28/CD3 CAR signal intensity was partly related to constitutive association of Lck with this domain in CAR complexes. Our data show that CAR signaling pathways cannot be predicted solely by the domains used to construct the receptor and that signal strength is a key determinant of T cell fate. Thus, tailoring CAR design based on signal strength may lead to improved clinical efficacy and reduced toxicity.
INTRODUCTION
Synthetic receptors that mimic natural T cell signaling cascades are being developed as immunotherapeutic reagents for cancer, autoimmunity, and infections. Chimeric antigen receptors (CARs), chimeric costimulatory receptors, and engineered T cell receptors (TCRs) can be introduced into T cells by gene transfer to redirect specificity and promote signaling pathways that initiate effector T cell functions (1) . The most successful of these novel therapeutics to date are CARs, which are composed of an extracellular antigenspecific single-chain variable immunoglobulin fragment (scFv) fused to intracellular signaling domains that activate T cells upon ligand binding (2) . Although treatment with CAR T cells can result in the complete remission of relapsed or refractory B cell malignancies, it can also cause life-threatening toxicities including cytokine release syndrome (CRS) and neurotoxicity (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) . Both efficacy and toxicity result from activation of intracellular signaling pathways mediated by CAR engagement.
T cell activation occurs after TCR engagement with antigenspecific peptide bound within the major histocompatibility complex (MHC). TCR binding stimulates intracellular phosphorylation of immunoreceptor tyrosine-based activating motifs (ITAMs) on the CD3, , , and  chains of the TCR (13) . Combined with protein phosphorylation signals delivered in trans from costimulatory molecules and cytokines, these events alter T cell transcriptional programs, induce proliferation, promote cytotoxic functions, and stimulate cytokine release. Most CARs use a simplified format to recapitulate the signals necessary for T cell effector function and proliferation. CAR constructs combine the CD3 endodomain in a single chain with a costimulatory domain from CD28 or 4-1BB. Both CD28/CD3 and 4-1BB/CD3 CAR T cells are effective for treating patients with B cell malignancies but may behave differently in vivo. CD28/CD3 CAR T cells generally undergo intense proliferation within 7 days of adoptive transfer and seldom persist more than 60 days after infusion (7, 14) . In contrast, 4-1BB/CD3 CAR T cells reach peak number by 7 to 14 days after transfer and can persist for several months (8, 15) . However, variability in patient cohorts, CAR structures, and clinical trial designs impede robust comparisons across trials. Studies comparing CD28/CD3 and 4-1BB/CD3 CAR T cells in vitro and in animal models partially explain these clinical differences by demonstrating that 4-1BB/CD3 CAR T cells have greater mitochondrial mass and a more memory T cell-like surface phenotype, and better retain effector functions in settings of chronic antigen stimulation (16, 17) .
It is widely assumed that the differences in phenotype and function of CD28/CD3 and 4-1BB/CD3 CAR T cells are conferred by activation of divergent signaling pathways through the distinct CAR costimulatory molecule domains. Analyses of signaling pathways stimulated by 4-1BB/CD3 or third-generation CD28/4-1BB/ CD3 CARs performed using phospho-flow cytometry, Western blot, or blot array do not identify differences between CD28/CD3 and 4-1BB/CD3 CAR signaling modules and only profile a small number of known signaling events to which there are experimentally validated antibodies (18, 19) . A more comprehensive, unbiased and quantitative approach to examine CAR signaling would be to use liquid chromatography-tandem mass spectrometry (LC-MS/ MS). When applied to study TCR signaling, LC-MS/MS uncovered hundreds of novel phosphoprotein signaling events that were missed by antibody-based techniques (20) (21) (22) (23) (24) .
Here, we used LC-MS/MS to analyze CAR stimulation-induced signaling events in primary human CD8 + T cells that express clinically relevant CD28/CD3 or 4-1BB/CD3 CARs specific for CD19 or ROR1. We found that stimulation through CD28/CD3 and 4-1BB/CD3 CARs produced nearly identical protein phosphorylation events. Instead, stimulation of CD28/CD3 CAR T cells prompted more rapid and intense phosphorylation of signaling intermediates and a more effector cell-like phenotype than stimulation of 4-1BB/ CD3 CAR T cells. CD28/CD3 CAR T cells were less potent at eradicating disseminated lymphoma in a xenograft mouse model than 4-1BB/CD3 CAR T cells. Increased basal phosphorylation of the CAR CD3 chain and CAR-associated Lck contributed to the rapid kinetics and stronger signal strength of CD28/CD3 CARs. Thus, the major distinction between CD28/CD3 and 4-1BB/CD3 CARs related not to divergent phosphoprotein signaling pathways but rather signaling strength and kinetics, which, in turn, affect T cell function and fate. These results may inform the design of new therapeutic receptors.
RESULTS

CAR designs containing a Strep-tag II sequence enable selective activation of CAR signaling in primary T cells
TCR signaling has been studied using LC-MS/MS analysis of transformed Jurkat T cells stimulated with anti-CD3 monoclonal antibodies (mAbs) (20, 21, 24) . Jurkat cells were selected for signaling studies because of the ease at which they can be grown and manipulated with common molecular biology techniques. Primary T cells from human subjects are more appropriate for studying CAR signaling, and we previously developed a method to activate CAR signaling in T cells without the need for ligand-expressing stimulator cells (25) . We modified two lentiviral vectors encoding CD19-and ROR1-specific 4-1BB/CD3 CARs that are currently being tested in clinical trials by adding a nine-amino acid Strep-tag II (STII) sequence to the extracellular CAR hinge. For comparison, we cloned structurally identical CD19-and ROR1-specific CD28/CD3 CARs containing the STII tag (Fig. 1A) . All constructs contained a truncated epidermal growth factor receptor (EGFRt) marker downstream of a T2A ribosomal skip element for purification of CAR-expressing T cells (26) . Inclusion of the STII sequence does not interfere with CAR T cell recognition or function, and STII CD28/CD3 or 4-1BB/ CD3 CAR T cells are efficiently activated and expanded in vitro by simulation with STII microbeads (Fig. 1B) (25) . Primary CD8 + T cells were transduced with each lentiviral vector, sorted for EGFRt expression, and expanded to >1.6 × 10 8 cells with a single cycle of stimulation before subsequent analysis (Fig. 1C) . The abundance of CD28/ CD3 and 4-1BB/CD3 CARs of each scFv specificity was similar on the cell surface as measured by staining with STII mAb (Fig. 1D) . CAR T cells also expressed similar amounts of CD45RO, CD62L, CD27, and CD28 (Fig. 1E ), indicating that CAR T cells retained markers associated with memory and proliferative potential. We only detected small frequencies of PD-1-or Tim-3-positive CAR T cells, suggesting that the cells were not activated or exhausted after cell culture (Fig. 1E) . Accordingly, >85% of CD28/CD3 and 4-1BB/CD3 CAR T cells were in the G 0 -G 1 cell cycle phase, indicating that the cells were resting (Fig. 1F) .
We evaluated canonical T cell signaling events induced by STII ligation and found that cell-free STII microbead stimulation of CARs was similar to CAR antigen-expressing tumor cells. ROR1-specific 4-1BB/CD3 CAR T cells were incubated for 45 min with increasing amounts of STII microbeads or with ROR1-transduced K562 (K562/ ROR1) tumor cells, and CD3 Tyr 142 and SLP-76 Ser 376 were measured by Western blot. At the highest bead to CAR T cell ratio, the phosphorylation of CD3 and SLP-76 was grossly similar to that observed in lysates from CAR T cells stimulated with K562/ROR1 cells ( Fig. 1G and fig. S1A ). This bead-to-cell ratio was used for all subsequent experiments. Thus, STII microbead stimulation provided a precise method to selectively activate CAR signaling in primary T cells.
MS identifies common protein phosphorylation events after stimulation of CD28/CD3 or 4-1BB/CD3 CAR T cells
We performed LC-MS/MS analysis to interrogate the signaling pathways activated in CD28/CD3 or 4-1BB/CD3 CARs in an unbiased manner. Human T cells expressing CD28/CD3 or 4-1BB/ CD3 CARs were incubated with STII or uncoated (control) microbeads for 10 or 45 min ( Fig. 2A) . CD19-specific CAR T cells generated from two different donors were used in two independent experiments, and a third independent experiment used ROR1-specific CAR T cells derived from one of the two donors (Fig. 2B) . Given that ROR1-and CD19-specific CARs displayed similar phenotypes across the two donors and were stimulated identically in a ligandindependent manner, the corresponding measurements were considered biological replicates. To provide relative quantitation of phosphopeptides within each experiment, we labeled each trypsindigested lysate with a unique isobaric tandem mass tag (TMT) and globally enriched for phosphopeptides by both phosphorylated tyrosine (pTyr) immunoprecipitation and immobilized metal affinity chromatography (IMAC) (27) (fig. S1B ). We identified a total of 26,804 phosphorylation sites across the three experiments corresponding to 4849 proteins. Among phosphorylation sites, 571 (2.13%) were pTyr, 4647 (17.33%) were phosphorylated threonine (pThr), and 21,586 (80.53%) were phosphorylated serine (pSer). (Fig. 2C) . Considering the stochastic limitations inherent in data-dependent acquisition shotgun prote omics (28), we found considerable overlap in the captured phos pho proteome between replicate experiments (Fig. 2D) . As previously described in murine T cells, 99% of phosphorylation sites detected in each experiment were present in both unstimulated and stimulated T cell lysates, enabling quantitation of changes induced by CAR activation (22, 29) .
We analyzed well-described TCR phosphorylation events within the MS data set to identify sites that were modified by CAR engagement (13) . We calculated the log 2 of the fold-change (log 2 FC) value for all phosphoryl ation sites within each experiment by comparing stimulated samples to appropriate controls (that is, CD28/CD3 CAR 10-min stimulation versus CD28/CD3 CAR 10-min control). At 10 min, phosphorylation of CD3 at Tyr 83 , Tyr 111 , and Tyr 142 , was increased in stimulated CAR T cells (Fig. 2E ). All CAR T cells displayed increased phosphorylation of CD28 at Tyr 209 after 10 min, which demonstrated that 4-1BB/CD3 CAR activation stimulates phosphorylation of endogenous CD28. After 45 min of stimulation, phosphoprotein signaling spread to downstream TCR nodes, and we measured increased phosphorylation of phospholipase C-1 (PLC-1) at Ser 1248 and BCL10 at Ser 138 ( Fig. 2E) (30, 31) . We did not observe reproducible changes at either time point in the phosphorylation of CD3, , or  ITAMs. Because these sites are phosphorylated after TCR stimulation (13) , our data indicated that CAR signaling only partially mimics endogenous TCR activation.
The MS data suggested that CD28/CD3 CAR stimulation may initiate a greater magnitude log 2 FC than 4-1BB/CD3 CARs at both 10 and 45 min, and we confirmed this finding by Western blot. Evaluation of cell lysates for CD3 pTyr 142 , ZAP-70 pTyr 319 , and PLC-1 pTyr 783 demonstrated that both CD28/CD3 and 4-1BB/ CD3 CAR stimulation increased phosphorylation of these sites, but we observed more intense ZAP-70 and CAR CD3 phosphorylation in stimulated CD28/CD3 CAR T cells compared to 4-1BB/ CD3 CAR T cells (Fig. 2F) . We also detected a low level of basal CAR CD3 phosphorylation in unstimulated CD28/CD3 CD19 and ROR1 CAR T cells that was not present in 4-1BB/CD3 CAR T cells. Western blot analysis of lysates from primary CD4 + T cells transduced with CD19 CARs and stimulated with STII microbeads also demonstrated similar patterns of basal CAR CD3 phosphorylation as well as more rapid and robust phosphorylation of CD3 and SLP-76 within CD28/CD3 CAR T cells ( fig. S2A ). Constitutive phosphorylation of the CAR CD3 domain or tonic signaling has been shown to occur with some CARs, including a CD19-specific CD28/CD3 CAR that is being used in the clinic (32) . Strong tonic signaling has been linked to sequences in the scFv that promote clustering of CAR molecules at the cell surface and results in the up-regulation of T cell exhaustion markers (33, 34) . Because we did not observe differences in PD-1 or Tim-3 expression, or evidence of CAR clustering in unstimulated CD28/CD3 or 4-1BB/CD3 CAR T cells (Fig. 1, E and F, and fig. S2B ), the low level of basal CAR CD3 domain phosphorylation detected here may be distinct from more extreme tonic signaling observed in some CARs with different scFv specificities.
Phosphorylation events mediated by CD28/CD3 or 4-1BB/CD3 CARs differ in kinetics and magnitude An advantage of shotgun MS is that it can quantitatively and temporally measure thousands of phosphorylation events outside of the canonical TCR signaling pathway to which there are no experimentally validated antibodies. We leveraged the limma statistical framework and associated R package to identify phosphorylation sites that were increased or decreased in abundance after CD28/CD3 and 4-1BB/CD3 CAR ligation (35) . We assigned a phosphorylation site to be CAR stimulation-responsive if it was detected in at least two of the three experiments, displayed an average |log 2 FC| ≥ 0.7 between stimulated and unstimulated conditions at 10 or 45 min, and met a 5% false discovery rate (FDR) cutoff. A log 2 (36, 37) . In contrast, no sites met log 2 FC and FDR criteria at 10 min after stimulation of 4-1BB/ CD3 CAR T cells (Fig. 3A and table S1 ). The lack of robust alterations in early protein phosphorylation in 4-1BB/CD3 CAR T cells was consistent with Western blot data showing a very low level of phosphorylation of CAR CD3, ZAP-70, and PLC-1 at 10 min after stimulation (Fig. 2F) .
After 45 min of stimulation, more intense changes in protein phosphoryl ation had occurred, and we detected phosphorylation at 1289 sites that met the log 2 FC and FDR cutoffs in either CD28/CD3 or 4-1BB/CD3 CAR T cell samples. These included 1279 phosphorylation sites from 743 gene products in CD28/CD3 CAR T cells and 522 sites from 346 gene products in 4-1BB/CD3 CAR T cells ( Fig. 3A and tables S2 and S3). These data indicated that stimulation of CD28/CD3 CAR T cells increased phosphorylation at a greater number of sites than did stimulation of 4-1BB/CD3 CAR T cells. However, both CD28/CD3 and 4-1BB/CD3 CAR activation stimulated highly similar changes in the phosphorylation of activation-responsive sites (Fig. 3B ). Only 12 (0.93%) of the 1289 phosphorylation sites that met the cutoffs in CD28/CD3 CAR samples exhibited an opposite response after 4-1BB/CD3 CAR stimulation, and only 43 (3.3%) sites exhibited a greater magnitude log 2 FC after 4-1BB/CD3 CAR stimulation. These observations were consistent with our earlier data suggesting that signaling downstream of CD28/CD3 CAR activation was more intense than downstream of 4-1BB/CD3 CAR activation. Furthermore, these subsets of 12 and 43 phosphorylation sites did not map to currently defined 4-1BB signaling networks (38) .
Finding relatively few differences in the phosphorylation events stimulated after activation of CD28/CD3 and 4-1BB/CD3 CARs was unexpected. When we questioned how proteins involved in the canonical T cell costimulatory signaling pathways were affected, we found that the phosphorylation of CD28 signaling intermediates VAV1, PIK3C2A, and PKCT was also increased after stimulation of both CD28/CD3 and 4-1BB/CD3 CAR T cells ( Fig. 3C) (39) . This result appeared to agree with our earlier observations that endogenous CD28 was phosphorylated after activation of 4-1BB/CD3 CAR T cells (Fig. 2E ). Within the 4-1BB signaling pathway, phosphorylation of lymphocyte-specific protein 1 (LSP1), a direct target of 4-1BB and TRAF2 signaling, was altered by stimulation of both CD28/CD3 and 4-1BB/CD3 CAR T cells (40) . Thus, rather than activating divergent costimulatory pathways, as might be predicted from the distinct costimulatory domains encoded by the receptors, activation of CD28/CD3 and 4-1BB/CD3 CARs induced highly similar changes in intracellular protein phosphorylation that encompassed both canonical CD28 and 4-1BB signaling intermediates.
A map illustrating the major pathways and individual protein phosphorylation events affected by CD28/CD3 and 4-1BB/CD3 CAR stimulation includes proteins involved in canonical TCR signaling and mitogen-activated protein kinase (MAPK) signaling pathways ( Fig. 4 and table S3 ). In addition, stimulation of either CD28/ CD3 or 4-1BB/CD3 CAR T cells affected phosphorylation of actincytoskeletal regulatory proteins, RNA processing proteins, nuclear pore proteins, and mitochondrial fission regulators such as DRP1 (41, 42) . A list of CAR stimulation-responsive phosphorylation sites is provided in tables S1 and S2. Many of these proteins have not been previously associated with TCR or CAR signaling.
Differences in the magnitude of CD28/CD3 and 4-1BB/CD3 CAR signaling persist across time Phosphorylation events activated by CD28/CD3 and 4-1BB/CD3 CAR T cell stimulation were highly similar but differed in intensity at the vast majority of sites. Signaling strength during T cell activation, measured as a composite of TCR affinity, costimulation, and cytokine signals, dictates clonal expansion and the effector capacities of a T cell response (43) (44) (45) . To provide a holistic measure of CAR signal strength, we sorted stimulation-responsive phosphorylation sites at 45 min from CD28/CD3 and 4-1BB/CD3 CAR samples by (table S4) . However, phosphorylation of the top 20 sites increased from control samples by 11.15-fold on average in CD28/CD3 CAR samples but only by 5.8-fold on average in 4-1BB/CD3 CAR samples (Fig. 3D) . Stratifying CAR stimulation-responsive phosphorylation sites by signaling pathway further indicated that the average phosphorylation site within the KEGG TCR signaling pathway was modulated by 2.52-fold in CD28/CD3 CAR samples but only by 1.69-fold in 4-1BB/CD3 CAR samples (Fig. 3E) . To determine whether 4-1BB/CD3 CAR signals reached a similar intensity to those of CD28/CD3 CARs at later times, we stimulated identically prepared CD8 + CAR T cells for 60, 120, or 180 min and measured phosphorylation of canonical and newly identified signaling intermediates (table S4) . Phosphorylation of PLC-1 Tyr 783 and DAPP1 Tyr 139 was apparent after stimulation of CD28/CD3 but not 4-1BB/CD3 CAR T cells (Fig. 3F ). These data suggest that 4-1BB/CD3 CAR stimulation may not achieve the same signal intensity as CD28/CD3 CAR T cells during this time frame.
Increased CAR signal intensity is associated with an effector cell-like phenotype and reduced in vivo antitumor activity
The strength of T cell activation and signal transduction influences transcriptional programs that regulate effector cell differentiation and memory formation (44) . We used RNA sequencing (RNA-seq) to analyze changes in transcription within CD28/CD3 or 4-1BB/ CD3 CD8 + CAR T cells at 6 hours after STII microbead stimulation.
Consistent with the faster and more intense phosphoprotein signal, CD28/CD3 CAR stimulation initiated more marked transcriptional changes. A comparison of stimulated to unstimulated CD28/CD3 CAR T cells identified 4894 differentially expressed genes at 6 hours, whereas 4-1BB/ CD3 CAR stimulation resulted in 197 differentially expressed genes. CD28/CD3 or 4-1BB/CD3 CAR stimulation increased expression of the canonical T cell activation marker CD69 to a similar degree (Fig. 5A ), but greater fold increases in expression of the effector molecules granzyme B (GZMB), interferon- (IFNG), interleukin-2 (IL2), tumor necrosis factor- (TNF), macrophage inflammatory protein 1 (CCL3), and macrophage inflammatory protein 1 (CCL4) were observed in CD28/CD3 CAR T cells (Fig. 5B ). Direct comparison of CD28/CD3 and 4-1BB/CD3 CAR T cells identified 1673 differentially expressed genes after stimulation (table S5) . Of these, Krüppel-like factor 2 (KLF2), IL-7 receptor (IL7R), and Rho family-interacting cell polarization regulator 2 (RIPOR2; previously known as FAM65B) expression was decreased in CD28/CD3 CAR T cells when compared to 4-1BB/CD3 CAR T cells (Fig. 5C ). KLF2 and IL7R are associated with memory T cell formation and are targets of the FOXO family of transcription factors (46) (47) (48) . Consistent with this observation, FOXO4 expression was reduced in stimulated CD28/CD3 CAR T cells when compared to 4-1BB/CD3 CAR T cells. Quantitative polymerase chain reaction (qPCR) confirmed that some of these T cell memory-associated genes were only differentially expressed in stimulated and not unstimulated CD28/CD3 or 4-1BB/ CD3 CAR T cells (Fig. 5D ).
Because differences in TCR signal quantity affect T cell functions (44, 45), we measured CD28/CD3 and 4-1BB/CD3 CAR T cell effector functions in vitro. We activated CD28/CD3 and 4-1BB/CD3 CAR T cells with ROR1-and CD19-expressing K562 cells or STII microbeads and measured cytokine production and proliferation. After 24 hours of coculture, CD28/CD3 CAR T cells secreted markedly more IFN-, IL-2, and TNF- than 4-1BB/CD3 CAR T cells (Fig. 5E) . By 72 hours, both CD28/CD3 and 4-1BB/CD3 CAR T cells proliferated (Fig. 5F ). These data suggested that stronger signaling by CD28/CD3 CAR T cells correlated with increased short-term effector responses.
We also investigated the function of CD28/CD3 and 4-1BB/ CD3 CAR T cells in vivo. For these studies, we used a defined 1:1 CD4/CD8 ratio CAR T cell product that displays superior control of xenograft Raji lymphoma in NOD/SCID/c −/− (NSG) mice (49) . Adoptive transfer of 3 × 10 6 CD28/CD3 or 4-1BB/CD3 CAR T cells into tumor-bearing mice mediated complete tumor regression (Fig. 5G) . However, when fewer (7.5-8 × 10 5 ) cells were transferred, CD28/CD3 CAR T cells were much less potent at eliminating Raji lymphoma cells than 4-1BB/CD3 CAR T cells, and all CD28/CD3 CAR T cell-treated mice died of tumor progression within 40 days ( Fig. 5, G and H) . Tumor progression occurred in mice treated at the lower CD28/CD3 CAR T cell dose despite accumulation of CAR T cells to higher frequencies in tumor-involved bone marrow (Fig. 5I) . CD28/ CD3 CAR T cells in the bone marrow expressed higher levels of PD-1, Lag-3, and Tim-3 ( Fig. 5J) , consistent with the acquisition of an exhausted phenotype. In summary, the rapid and intense signaling mediated by CD28/CD3 CAR activation correlated with an exhausted phenotype in CD8
+ and CD4 + CAR T cells and reduced antitumor activity. 
CD28/CD3 and 4-1BB/CD3 CARs differentially associate with endogenous CD28 and Lck
To interrogate possible causes of increased CD28/CD3 CAR signaling kinetics and strength, we immunoprecipitated CAR complexes from unstimulated CD8 + T cells and probed for differences among associated T cell signaling proteins in the basal state. Western blot confirmed efficient CAR pull-down and showed association of endogenous CD28 and Lck with the CD28/CD3 CAR but only minimal CD28 and Lck association with the 4-1BB/CD3 CAR (Fig. 6A) . Because basal CAR phosphorylation was conferred by the presence of the CD28 costimulatory domain and Tyr
206
, Tyr
209
, and Tyr 218 were intensely phosphorylated after CAR stimulation, we constructed CD28/CD3 CARs with tyrosine to phenylalanine mutations at these residues (Fig. 6B ). CD19 and ROR1 CARs with mutations of Y218F (Y1) or all three tyrosines (Y3) were efficiently expressed in T cells and led to vigorous IFN- production and proliferation in response to coculture with ROR1 + or CD19 + tumor cells (Fig. 6, C and D) . We observed partial (Y1) or complete (Y3) abrogation of basal CAR CD3 phosphorylation in CARs containing Y to F mutations as compared to CD28/CD3 CARs; however, Y1 and Y3 CARs still phosphorylated SLP-76 and PLC-1 with similar kinetics and intensity as the wild-type CD28/CD3 CAR after STII microbead stimulation (Fig. 6E) . Immunoprecipitation of each CAR indicated that Lck association was not abrogated by the Y1 and Y3 mutations, although endogenous CD28 did not associate with the Y3 CAR (Fig. 6F) . Together, these results suggested that neither basal CAR CD3 phosphorylation nor endogenous CD28 association was responsible for the increased signal kinetics and strength of CD28/CD3 CARs.
Constitutive Lck activation promotes T cell effector functions (50, 51) . Therefore, we tested whether association of Lck with CD28/CD3 CARs mediated rapid and robust phosphorylation of signaling intermediates after CAR activation. We generated proline to alanine mutations at the Lck binding site of CD28 (Fig. 7A) (52, 53) . Immunoprecipitation of the wild-type and mutant CD28/CD3 CARs showed that Lck association was absent in CARs with proline to alanine mutations ( Fig. 7 and fig. S4 ). Signaling analyses of these constructs demonstrated that mutation of proline residues alone in CD28P CARs partially abrogated basal CAR CD3 phosphoryl ation but did not reduce signal intensity (Fig. 7C) . However, simultaneous mutation of proline and tyrosine residues in Y3P CARs fully abrogated basal CAR phosphorylation and reduced the magnitude of SLP-76 and PLC-1 phosphorylation after stimulation (Fig. 7C) . Thus, differences in CAR signal intensity between CD28/CD3 CARs and 4-1BB/CD3 CARs were, in part, related to greater Lck association with CD28/CD3 CARs. These data suggest that CAR signal intensity could be altered by mutating tyrosine and proline residues in the CD28 signaling domain.
DISCUSSION
The adoptive transfer of CD28/CD3 or 4-1BB/CD3 CD19 CAR T cells is an effective therapy for patients with certain B cell malignancies but can cause serious toxicities that originate from CAR signaling after tumor recognition (1). However, CD28/CD3 or 4-1BB/ CD3 CAR signaling modules confer differences in effector functions and metabolic profiles, and both types of CAR T cells can cause serious toxicities that originate from CAR signaling after T cell activation (16, 17) . Crafting safer and more effective CAR T cells might be accomplished by modifying CAR design, but optimization is hindered by the rudimentary understanding of how signaling by synthetic CARs directs T cell functional outputs and cell fate decisions.
We used MS to study changes in the phosphoproteome of T cells after CAR ligation and captured 26,804 unique phosphorylation sites that describe changes induced by CD28/CD3 and 4-1BB/ CD3 CARs in detail. Our experiments used structurally identical CARs specific for two target antigens being pursued in clinical trials. In contrast to the current perception of how costimulatory domains function in CARs, our data show that, in the space of this data set, CD28/CD3 and 4-1BB/CD3 CAR activation initiated nearly identical directional changes in protein phosphorylation. Notably, both CARs altered phosphorylation of proteins involved in canonical TCR, CD28, and 4-1BB signaling pathways. Only 12 of 1289 (0.93%) phosphorylation sites exhibited opposite responses to stimulation when comparing CAR constructs at 45 min after activation, and these few sites are not directly linked to either CD28 or 4-1BB signaling pathways. Therefore, our data refute the notion that CD28/CD3 and 4-1BB/CD3 CARs activate divergent signaling cascades and indicate that one cannot predict the signaling cascades initiated by synthetic CARs by focusing solely on the domains encoded by the receptor polypeptide. Rather, synthetic CARs initiate a plethora of signals that both encompass and surpass those of the natural molecules on which the synthetic receptors are based.
Instead, our data demonstrate that a major difference between CD28/CD3 and 4-1BB/CD3 CARs is that CD28/CD3 receptors signal with markedly increased kinetics and intensity. Within 45 min, CD28/CD3 CAR stimulation altered the phosphorylation state of hundreds of proteins involved in TCR signaling, MAPK signaling, actin-cytoskeleton rearrangement, and RNA processing pathways. Alterations in protein phosphorylation after 4-1BB/CD3 CAR stimulation affected identical proteins as CD28/CD3 CAR stimulation but proceeded more slowly and with reduced intensity. Subsequent analysis of CAR binding partners demonstrated more Lck in immunoprecipitates from unstimulated CD28/CD3 CAR T cells than from 4-1BB/CD3 CAR T cells. Mutational analysis of the CAR CD28 signaling domain identified residues responsible for basal CAR CD3 phosphorylation as well as Lck association, and showed that abrogation of these features reduced CAR signal intensity. Thus, future analyses of novel CAR designs should consider how interactions with potential binding partners might affect signaling.
Our data also showed that the more rapid and intense phosphoprotein signaling in CD28/CD3 CAR T cells induced an effector celllike transcriptional profile and more robust T cell cytokine production early after CAR ligation, but less potent antitumor function in an in vivo tumor model of disseminated lymphoma. These data are consistent with previous findings that intense TCR signaling and IL-2 production promote differentiation of short-lived effector CD8 + T cells (54, 55) , and also support a model by which TCR and costimulatory signals sum linearly to affect cell fate (45) . Some amount of CD28 signaling is beneficial for T cell memory formation (56), and we found that the 4-1BB/CD3 CARs used in this study phosphorylated endogenous CD28 and activated the CD28 signaling pathway. However, encoding a fully functional CD28 signaling domain on a CAR polypeptide chain may yield excessive stimulation that increases the incidence of CRS, promotes T cell exhaustion, and reduces persistence. Indeed, analyses of acute lymphoblastic leukemia patients who were in morphologic relapse at the time of treatment with CD28/CD3 CAR T cells showed poor long-term CAR T cell persistence and low overall survival due to frequent relapse with CD19 + disease (57). CARs are often currently selected to maximize measures of in vitro T cell effector functions and proliferation, and our findings indicate that these selection criteria may not be optimal for predicting in vivo efficacy. Future optimizations to CAR design should consider both the signaling domains contained within the receptor, interactions with potential binding partners, and how modifications of costimulatory domains might tailor overall signal strength for downstream T cell functional outputs. Mutating the CAR CD28 signaling domain is a logical approach for reducing excessive signal strength, and further studies of mutated CAR signaling domains are warranted. However, variability in CAR structural features outside of the costimulatory CD28 or 4-1BB and CD3 signaling domains may limit the universality of this approach. Most CARs have a unique combination of scFv, hinge, and transmembrane domain, and this structural variation can affect CAR signaling and may alter association with endogenous T cell signaling molecules. For instance, the CAR CD28 transmembrane domain used in this study may have influenced association with endogenous CD28 and Lck. Further immunoprecipitation analysis of CARs with CD8 transmembrane domains and other structural features could answer this question (3) .
Our approach evaluating CD28/CD3 and 4-1BB/CD3 CAR signaling using a cell-free stimulation method has the advantage of identifying phosphorylation events induced by the synthetic receptors in isolation. Although this approach did not integrate the multitude of other events that may occur when CAR T cells encounter tumor cells in vivo (58), it could be extended to interrogate cross-talk between CAR signaling and costimulatory or inhibitory pathways by immobilizing various ligands onto the magnetic beads. Our approach was also not designed to compare TCR and CAR signaling. A direct comparison of TCR and CAR ligation-induced phosphoprotein signaling is likely to be valuable and is a focus of ongoing research. Thus, MS analysis can provide important insights into CAR signaling that will affect next-generation CAR designs.
MATERIALS AND METHODS
Acquisition of peripheral blood T cells from healthy donors
Healthy adults (>18 years old) were enrolled in an institutional review board-approved study for peripheral blood collection. Cell culture 293T Lenti-X cells (Clontech) were cultured in Dulbecco's modified Eagle's medium (Gibco) supplemented with 10% fetal bovine serum, 1 mM l-glutamine (Gibco), 25 mM Hepes (Gibco), and penicillin/ streptomycin (100 U/ml; Gibco). K562 (CCL-243) and Raji (CCL-86) cells were obtained from the American Type Culture Collection and cultured in RPMI 1640 (Gibco) supplemented with 5% fetal bovine serum, 1 mM l-glutamine, 25 mM Hepes, and penicillin/streptomycin (100 U/ml). Primary human T cells were cultured in CTL medium consisting of RPMI 1640 supplemented with 10% human serum, 2 mM l-glutamine, 25 mM Hepes, penicillin/streptomycin (100 U/ml), 50 M -mercaptoethanol (Sigma), and human IL-2 (50 U/ml; Prometheus). All cells were cultured at 37°C and 5% CO 2 and tested bimonthly for the absence of mycoplasma using the MycoAlert Mycoplasma Detection Kit (Lonza).
Generation of CARs and recombinant lentiviral vectors
CD19-and ROR1-specific CAR constructs have been previously described (49, 59) . For work in this study, a single STII sequence and two G 4 S linkers were inserted between the FMC63 or R12 scFv and immunoglobulin G4 (IgG4) hinge (25) . These were linked to the 27-amino acid transmembrane domain of human CD28 (UniProt: P10747) and to a signaling module comprising either (i) the 41-amino acid cytoplasmic domain of human CD28 with an LL→GG substitution located at positions 186 to 187 of the native CD28 protein (60) were generated by site-directed mutagenesis. All CAR constructs were linked by T2A sequence to EGFRt, codon-optimized, and cloned into an HIV7 lentiviral vector. For fluorescence microscopy, the CD3 endodomain was directly fused to enhanced green fluorescent protein (eGFP). To make CAR antigen-expressing K562 cells, amino acids 1 to 325 of human CD19 (UniProt: P15391) were cloned into an HIV7 lentiviral vector, and amino acids 1 to 937 of human ROR1 (UniProt: Q01973) were cloned into an mp71 retroviral vector, which was a gift of W. Uckert (Max Delbruck Center for Molecular Medicine). All cloning was performed by PCR, enzyme digest, and/or Gibson assembly. Plasmids were verified by capillary sequencing and restriction digest.
Lentivirus preparation and transduction
To prepare CAR T cells, Lenti-X cells were transiently transfected with the HIV7 CAR vector, as well as psPAX2 (Addgene plasmid no. 12260) and pMD2.G (Addgene plasmid no. 12259) packaging plasmids. One day later (day 1), primary T cells were activated using Dynabeads Human T-Activator CD3/CD28 (Thermo Fisher Scientific) and cultured in CTL supplemented with IL-2 (50 U/ml). On the next day (day 2), lentiviral supernatant was harvested from Lenti-X cells, filtered using 0.45-m polyethersulfone (PES) syringe filters (Millipore), and added to activated T cells. Polybrene (Millipore) was added to reach a final concentration of 4.4 g/ml, and cells were spinoculated at 800g and 32°C for 90 min. Viral supernatant was replaced 8 hours later with fresh CTL supplemented with IL-2 (50 IU/ml). Half-media changes were then performed every 48 hours using CTL supplemented with IL-2 (50 U/ml). Dynabeads were removed on day 6; CD8 + EGFRt + -transduced T cells were FACS (fluorescence-activated cell sorting)-purified on a FACSAriaII (BD Biosciences) on day 9.
To prepare K562/CD19 cells, Lenti-X cells were transiently transfected with psPAX2, pMD2.G, and an HIV7 lentiviral vector encoding CD19. To prepare K562/ROR1 cells, Lenti-X cells were transiently transfected with MLV g/p, 10A1, and an mp71 retroviral vector encoding ROR1. To prepare Raji/ffluc cells, Lenti-X cells were transiently transfected with psPAX2, pMD2.G, and an HIV7 lentiviral vector encoding GFP and firefly luciferase. Two days later, viral supernatant was filtered using a 0.45-m PES syringe filter and added to K562 or Raji cells. Five days later, transduced cells were stained with mAbs specific for CD19 (HIB19, BioLegend) or ROR1 (2A2, Miltenyi Biotec) and FACS-purified on a FACSAria II to greater than 97% purity.
T cell expansion for MS and functional analyses FACS-purified CD8
+ EGFRt + cells were expanded over a single stimulation cycle before MS and/or functional analyses. CD19-specific CAR T cells were expanded by coculture with irradiated CD19 + lymphoblastoid cell lines (LCLs) in a 1:7 (T cell/LCL) ratio and assayed 8 days after stimulation. ROR1-specific CAR T cells were expanded using a rapid expansion protocol containing purified OKT3, irradiated LCL, and irradiated PBMCs and were assayed 11 days after stimulation. During expansion, cultures were fed with fresh CTL media containing IL-2 (50 IU/ml) every 2 to 3 days.
Flow cytometry and cell phenotyping T cells were stained with a 1:100 dilution of fluorophore-conjugated mAbs specific for human CD4 (RPA-T4), CD8 (SK1), CD27 (M-T271), CD28 (CD28.2), CD45 (HI30), CD45RO (UCHL1), CD62L (DREG-56), CD223 (3DS223H), CD279 (eBioJ105), or CD366 (F38-2E2) purchased from BD Biosciences, Thermo Fisher Scientific, or BioLegend. T cells were also stained with isotype control fluorophore-conjugated antibodies when appropriate. Cetuximab (anti-EGFR, Bristol-Myers Squibb) and 3E8 [anti-STII, Fred Hutchinson Cancer Research Center (FHCRC)] were biotinylated using the EZ-Link Sulfo-NHS-Biotin Kit (Thermo Fisher Scientific) followed by cleanup with the Zeba Spin Desalting Column (Thermo Fisher Scientific) and used to stain T cells in conjunction with streptavidin-allophycocyanin (Thermo Fisher Scientific). DNA content staining was performed by fixing T cells with 70% ice-cold ethanol, permeabilizing cells with 1% Triton X-100 (Sigma), degrading RNA with ribonuclease A (100 g/ml; Thermo Fisher Scientific), and staining DNA with propidium iodide (20 g/ml; Thermo Fisher Scientific). All data were collected on a FACSCanto II or FACSAria II (BD Biosciences).
STII and control microbead preparation
Streptavidin-coated magnetic particles (1 ml; Spherotech) were washed once in excess 1× PBS supplemented with penicillin/streptomycin (100 U/ml) (PBS + P/S) using a benchtop magnet. STII microbeads were prepared by resuspending beads in PBS + P/S (1 ml) and then slowly adding 16.67 g of STII biotin mAb (GenScript) while vortexing. Beads were incubated overnight at 4°C on a three-dimensional orbital shaker, washed three times with excess PBS + P/S using a benchtop magnet, and resuspended in PBS + P/S (4 ml). To make control beads, streptavidin-coated magnetic particles (1 ml) were washed once using a benchtop magnet and resuspended in PBS + P/S (4 ml). Beads were stored at 4°C.
Cell stimulations, protein lysates, and RNA isolation CAR T cells were washed and resuspended in warm CTL medium at a concentration of 2 × 10 7 cells/ml. Cells were then incubated with STII or control microbeads at a ratio of 30 l of beads per 1 × 10 6 cells in a 37°C water bath. After the allotted time, cells were quickly washed twice using ice-cold PBS and lysed in a 6 M urea, 25 mM tris (pH 8.0), 1 mM EDTA, 1 mM EGTA solution supplemented with protease (Sigma) and phosphatase inhibitors (Sigma) at a 1:100 dilution, hereon referred to as lysis buffer. Lysates were sonicated for 15 s before centrifuging at 10,000g and 4°C for 10 min. Beads were removed during lysate clearing. After 6 hours of stimulation, RNA isolations were performed using a NucleoSpin RNA kit (Macherey-Nagel) according to the manufacturer's instructions. Beads were removed using a benchtop magnet before cell lysis and RNA extraction.
Protein digestion, TMT labeling, and pTyr peptide immunoprecipitation Protein was quantified in lysates by Micro BCA Assay (Thermo Fisher Scientific), and lysates were diluted to 2 mg/ml using lysis buffer. Lysates were reduced in 24 mM TCEP [tris(2-carboxyethyl) phosphine hydrochloride] (Thermo Fisher Scientific) for 30 min at 37°C with shaking, followed by alkylation with 48 mM iodoacetamide (Sigma) in the dark at room temperature for 30 min. Lysates were then diluted with 200 mM tris (pH 8.0) to a urea concentration of 2 M. Lys-C (Wako) was dissolved in 25 mM tris (pH 8.0) at 200 g/ml and added to lysates at 1:100 (enzyme/protein) ratio by mass and incubated for 2 hours at 37°C with shaking. Samples were further diluted with 200 mM tris (pH 8.0) to a urea concentration of 1 M before adding trypsin at a 1:50 trypsin/protein ratio. After 2 hours, a second trypsin aliquot was added at a 1:100 trypsin/protein ratio. Digestion was carried out overnight at 37°C with shaking. After 16 hours, the reaction was quenched with formic acid (FA) to a final concentration of 1% by volume. Samples were desalted using Oasis HLB 96-well plates (Waters) and a positive pressure manifold (Waters). The plate wells were washed with 3 × 400 l of 50% MeCN/0.1% FA and then equilibrated with 4 × 400 l of 0.1% FA. The digests were applied to the wells and then washed with 4 × 400 l of 0.1% FA before being eluted drop by drop with 3 × 400 l of 50% MeCN/0.1% FA. The eluates were lyophilized, followed by storage at −80°C until use. For TMT labeling (Thermo Fisher Scientific), desalted peptides were resuspended in 50 mM Hepes at 1 mg/ml based on starting protein mass. TMT reagents were resuspended in 257 l of MeCN and transferred to the peptide sample. Samples were incubated at room temperature for 1 hour with mixing. Labeling reactions were quenched by the addition of 50 l of 5% hydroxyl amine (Sigma) and incubated for 15 min at room temperature with mixing. The independent labeling reactions were then pooled together and lyophilized. The labeled peptides were desalted as above and then lyophilized and stored at −80°C. Immunoprecipitation of pTyr peptides was performed using the PTMScan P-Tyr-1000 Kit (Cell Signaling Technology). The enriched pTyr peptide fraction was purified using a C18 Spin Tip (Thermo Fisher Scientific), lyophilized, and stored at −80°C until analysis. The flow-through fraction was desalted, lyophilized, and stored at −80°C.
Basic (high-pH) reversed-phase LC
The desalted and pTyr peptide-depleted flow-through was fractionated by high-pH reversed-phase (RP) LC. Protein digest (4 mg) was loaded onto an LC system consisting of an Agilent 1200 highperformance LC with mobile phases of 5 mM NH 4 HCO 3 (pH 10) (A) and 5 mM NH 4 HCO 3 in 90% MeCN (pH 10) (B). The peptides were separated by a 4.6 mm × 250 mm Zorbax Extend-C18, 3.5 m, column (Agilent) over 96 min at a flow rate of 1.0 ml/min by the following timetable: hold 0% B for 9 min, gradient from 0 to 10% B for 4 min, 10 to 28.5% B for 50 min, 28.5 to 34% B for 5.5 min, 34 to 60% B for 13 min, hold at 60% B for 8.5 min, 60 to 0% B for 1 min, reequilibrate at 0% B for 5 min. Fractions were collected at 1-min intervals from 0 to 96 min by the shortest path by row in a 1-ml deep well plate (Thermo Fisher Scientific). The high-pH RP fractions were concatenated into 24 samples by every other plate column starting at 15 min (for example, sample 1 contained fractions from wells B10, D10, F10, etc.). The remaining fractions were combined such that fractions from 12 to 14 min were added to sample 1, all fractions after 86 min were added to sample 24, and all fractions from 0 to 11 min were combined into sample "A." Ninety-five percent of every 12th fraction of the 24 samples was combined (1,13; 2,14;…) to generate 12 more samples, which were dried down and stored at −80°C before phosphopeptide enrichment by IMAC.
Immobilized metal affinity chromatography IMAC enrichment was performed using Ni-NTA agarose beads (Qiagen) stripped with EDTA and incubated in a 10 mM FeCl 3 solution to prepare Fe 3+ -NTA agarose beads. Fractionated lysate was reconstituted in 200 l of 0.1% trifluoroacetic acid (TFA) in 80% MeCN and incubated for 30 min with 100 l of the 5% bead suspension while mixing at room temperature. After incubation, beads were washed three times with 300 l of 0.1% TFA in 80% MeCN. Phosphorylated peptides were eluted from the beads using 200 l of 70% acetonitrile, 1% ammonium hydroxide for 1 min with agitation at room temperature. Samples were transferred into a fresh tube containing 60 l of 10% FA, dried down, and resuspended in 0.1% FA and 3% MeCN. Samples were frozen at −80°C until analysis.
Nano-LC-MS/MS
Phosphopeptide-enriched samples were analyzed by LC-MS/MS on an Easy-nLC 1000 (Thermo Fisher Scientific) coupled to an LTQOrbitrap Fusion mass spectrometer (Thermo Fisher Scientific) operated in positive ion mode. The LC system, configured in a vented format, consisted of a fused-silica nanospray needle [PicoTip emitter, 50 m inside diameter (ID) × 20 cm, New Objective] packed in-house with ReproSil-Pur C18-AQ, 3 m, and a trap (IntegraFrit Capillary, 100 m ID × 2 cm, New Objective) containing the same resin as in the analytical column with mobile phases of 0.1% FA in water (A) and 0.1% FA in MeCN (B). The peptide sample was diluted in 20 l of 0.1% FA, 3% MeCN, and 8.5 l was loaded onto the column and separated over 210 min at a flow rate of 300 nl/min with a gradient from 5 to 7% B for 2 min, 7 to 35% B for 150 min, and 35 to 50% B for 1 min, hold 50% B for 9 min, 50 to 95% B for 2 min, hold 95% B for 7 min, 95 to 5% B for 1 min, reequilibrate at 5% B for 38 min. A spray voltage of 2000 V was applied to the nanospray tip. MS/MS analysis occurred over a 3-s cycle time consisting of one full-scan MS from 350 to 1500 mass/charge ratio (m/z) at a resolution of 120,000, followed by data-dependent MS/MS scans using high-energy collision dissociation activation with 27% normalized collision energy of the most abundant ions. Selected ions were dynamically excluded for 45 s after a repeat count of 1.
Immunoprecipitation
Protein G Dynabeads (Thermo Fisher Scientific) were incubated with anti-STII antibody (GenScript) for 60 min, cross-linked for 30 min using 20 mM dimethyl pimelimidate (Thermo Fisher Scientific) diluted in 200 mM triethanolamine (Thermo Fisher Scientific), quenched with 150 mM monoethanolamine (Thermo Fisher Scientific), and washed three times with 1× PBS. T cells were lysed in NP40 Cell Lysis Buffer (Thermo Fisher Scientific) supplemented with protease and phosphatase inhibitors. Lysates were incubated on ice for 15 min and then centrifuged at 10,000g and 4°C for 10 min. Immunoprecipitations were performed according to the manufacturer's instructions, where Dynabeads were incubated with equal masses of cleared lysates for 90 min at room temperature. RNA sequencing RNA was extracted from 24 samples from three donors. Total RNA integrity was checked using an Agilent 4200 TapeStation (Agilent Technologies) and quantified using a Trinean DropSense96 spectrophotometer (Caliper Life Sciences). RNA-seq libraries were prepared from total RNA using the TruSeq RNA Sample Prep Kit v2 (Illumina) and a Sciclone NGSx Workstation (PerkinElmer). Library size distributions were validated using an Agilent 4200 TapeStation. Additional library quality control, blending of pooled indexed libraries, and cluster optimization were performed using a Qubit 2.0 Fluorometer (Thermo Fisher Scientific). RNA-seq libraries were pooled (6-to 8-plex) and clustered onto a flow cell lane. Sequencing was performed using an Illumina HiSeq 2500 in rapid mode using a paired-end, 50-base read length sequencing strategy.
Western blotting
Quantitative polymerase chain reaction RNA was extracted, and total RNA integrity was verified using an Agilent 4200 TapeStation (Agilent Technologies). RNA (500 ng) was used to prepare complementary DNA (cDNA) with SuperScript III (Thermo Fisher Scientific). cDNA (15 ng) was added to a reaction with TaqMan Universal Master Mix II with uracil N-glycosylase (Thermo Fisher Scientific) and one of the following Thermo Fisher Scientific TaqMan assay probes: Hs00172973_m1 (FOXO4), Hs00902234_m1 (IL7R), Hs00360439_g1 (KLF2), or Hs99999907_m1 (B2M). Reactions were run in duplicate or triplicate on one 384-well plate. C t values were calculated by dividing mean C t of technical replicates from FOXO4, IL7R, and KLF2 probes by the mean C t of the housekeeping gene 2 microglobulin (B2M). CD28/CD3 versus 4-1BB/ CD3 ratios for each donor were calculated and subjected to a log 2 transformation.
In vitro functional assays CAR T cells were cocultured with K562, K562/CD19, or K562/ROR1 cells at a T cell-to-tumor cell ratio of 2:1. In some experiments, CAR T cells were also incubated with control or STII microbeads at a ratio of 30 l of beads per 1 × 10 6 cells. Cytokine concentrations in cellular supernatant were quantified by ELISA (Thermo Fisher Scientific) 24 hours after stimulation. T cell proliferation was quantified by staining CAR T cells with a 0.2 M solution of CFSE dye (Thermo Fisher Scientific) and incubating CAR T cells with K562/ CD19 cells, K562/ROR1 cells, control beads, or STII microbeads for 72 hours.
Transfer of T cells in NSG mice
Six-to 8-week-old male or female NSG mice were obtained from the Jackson Laboratory or bred in-house. Mice were engrafted via tail vein with 5 × 10 5 CD19 + Raji/ffluc cells and, 7 days later, injected intravenously with PBS or a defined product of purified CD8 + and CD4 + CD19-specific CAR T cells mixed together in a 1:1 ratio. Bioluminescence imaging was performed as described (49) . Mice were either followed for survival or sacrificed on day 20 for analysis of T cell frequencies and phenotypes by flow cytometry. Peripheral blood was extracted, red blood cells were lysed using ACK Lysing Buffer (Thermo Fisher Scientific), and remaining cells were stained with fluorochromelabeled mAbs. Bone marrow was isolated from hindlimbs by mechanical disruption, followed by red blood cell lysis, and staining with fluorochrome-labeled mAbs. Mice handlers were blinded to group allocation. The FHCRC Institutional Animal Care and Use Committee approved all experimental procedures.
Fluorescence microscopy CD8 + T cells from healthy donors were transduced as previously described. Instead of FACS purification on day 9, cells were imaged on a DeltaVision Elite microscope (GE Healthcare). At least eight cells were visualized per condition. Raw images were subjected to a linear adjustment of brightness and contrast using ImageJ (NIH).
Shotgun MS data analysis
Raw MS/MS spectra from each replicate experiment were searched together against the reviewed Human Universal Protein Resource (UniProt) sequence database (release 2016_01) with common laboratory contaminants using the MaxQuant/Andromeda search engine version 1.6.0.1 (61) . The search was performed with a tryptic enzyme constraint for up to two missed cleavages. Variable modifications were oxidized methionine, pSer, pThr, and pTyr. Carbamidomethylated cysteine was set as a static modification. Peptide MH+ mass tolerances were set at 20 parts per million (ppm). The overall FDR was set at ≤1% using a reverse database target decoy approach.
For the three TMT experiments, phosphopeptide site localization was determined by MaxQuant and converted to phosphorylation sites using Perseus version 1.6.0.7 (62) . At this step, reverse hits and potential contaminants were excluded from further analysis. Data normalization was performed by scaling each TMT channel to the channel median, followed by a log 2 transformation. Stimulation versus control ratios were calculated by subtracting the appropriate control channels from stimulated channels. Because of incomplete MS sampling, some phosphorylation sites (features) were only found in one or two replicate experiments, and a much smaller minority (<1%) of sites were not found in every TMT channel.
Differential expression analyses over phosphorylation sites were performed using the limma statistical framework and associated R package (35, 63) . For these analyses, we chose to keep only features that had values in at least two experiments and all TMT channels, leaving us with 14,490 quantified phosphorylation sites. A linear model was fitted to each phosphorylation site, and empirical Bayes moderated t statistics were used to assess differences in expression/abundance. Contrasts comparing stimulation versus control treatments were tested. Intraclass correlations were estimated using the duplicate correlation function of the limma package to account for measures originating from the same patients and the same antigens (64) . An absolute log 2 FC cutoff (stimulation versus control) of 0.7 and an FDR cutoff of 5% were used to determine differentially expressed phosphorylation sites. Analyses of signaling networks and KEGG pathways were performed using StringDB.
RNA-seq data analysis
Image analysis and base calling were performed using Illumina's Real Time Analysis v1.18 software, followed by "demultiplexing" of indexed reads and generation of FASTQ files, using Illumina's bcl2fastq Conversion Software v1.8.4. The RNA-seq data were aligned to the human genome (University of California, Santa Cruz Human Genome Assembly GRCh38 reference) using STAR (Spliced Transcripts Alignment to a Reference), and gene quantification was performed using RSEM (RNA-Seq by Expectation Maximization) (65, 66) . Genes with less than 10 nonzero read counts (taking into account technical replicates) were discarded, leaving 18,498 expressed genes. All libraries passed the quality control criteria (libraries with more than 200,000 reads, 12,000 detected genes, and an exon range > 60%). Raw count data were imported into R. edgeR was used to calculate the normalization factors to scale the raw library sizes, followed by a voom transformation from the limma Bioconductor package (67, 68) . It transforms count data to log 2 counts per million and estimates the mean-variance relationship to compute appropriate observation-level weights. Linear models with subject random effects were again used for differential gene expression analysis as described in the "Shotgun MS data analysis" section. Contrasts comparing treatments (control versus stimulation) or CARs (CD28/CD3 versus 4-1BB/CD3) were tested. An absolute log 2 FC cutoff of 1 and an FDR cutoff of 1% were used to determine differentially expressed genes. Table S1 . CAR stimulation-responsive phosphorylation sites after 10 min. Table S2 . CAR stimulation-responsive phosphorylation sites after 45 min. Table S3 . KEGG pathways identified by StringDB after 45 min of CAR stimulation. Table S4 . Phosphorylation sites increased by CAR stimulation at 45 min. Table S5 . Differentially expressed genes between stimulated CD28/CD3 and 4-1BB/CD3 CAR T cells.
Analysis of T cell phenotype, function, and in vivo experiments
